2009 Pandemic Influenza A (H1N1) Fatal Case Series Investigation Team members are in Appendix.
Epidemiology of influenza A (H1N1)pdm09-associated deaths in the United States, September–October 2009
Article first published online: 16 JUL 2012
© 2012 Blackwell Publishing Ltd
Influenza and Other Respiratory Viruses
Volume 6, Issue 6, pages e169–e177, November 2012
How to Cite
Regan, J., Fowlkes, A., Biggerstaff, M., Jhung, M. A., Gindler, J., Kennedy, E., Fields, V., Finelli, L. and for the 2009 Pandemic Influenza A (H1N1) Fatal Case Series Investigation Team (2012), Epidemiology of influenza A (H1N1)pdm09-associated deaths in the United States, September–October 2009. Influenza and Other Respiratory Viruses, 6: e169–e177. doi: 10.1111/j.1750-2659.2012.00408.x
- Issue published online: 16 OCT 2012
- Article first published online: 16 JUL 2012
- Accepted 5 May 2012. Published Online 16 July 2012.
- H1N1pdm09 subtype;
- influenza A virus;
- influenza antiviral agents;
- influenza fatal cases
- Top of page
- Conflicts of interest
Please cite this paper as: Regan et al. (2012) Epidemiology of influenza A (H1N1)pdm09-associated deaths in the United States, September–October 2009. Influenza and Other Respiratory Viruses 6(601), e169–e177.
Background From April to July 2009, the United States experienced a wave of influenza A (H1N1)pdm09 virus (H1N1pdm09) infection. The majority of the deaths during that period occurred in persons <65 years of age with underlying medical conditions.
Objective To describe the epidemiology of H1N1pdm09-associated deaths in the US during the fall of 2009.
Methods We collected demographic, medical history, and cause of death information on a nationally representative, stratified random sample of 323 H1N1pdm09-associated deaths that occurred during September 1–October 31, 2009.
Results Data were available for 302/323 (93%) deaths. Most cases (74%) were 18–64 years of age and had ≥1 underlying medical condition (72%). Among cases aged <18 years, 16/43 (37%) had a chronic lung disease, and 15/43 (35%) a neurological disorder; among cases aged ≥18 years, 94/254 (37%) had a chronic lung disease and 84/254 (33%) had a metabolic disorder. The median number of days between symptom onset and death was six among children (range, 1–48) and 12 among adults (range, 0–109). Influenza antiviral agents were prescribed for 187/268 (70%) of cases, but only 48/153 (31%) received treatment within 2 days of illness onset.
Conclusions The characteristics of H1N1pdm09 deaths identified during the fall of 2009 were similar to those occurring April–July 2009. While most cases had conditions that were known to increase the risk for severe outcomes and were recommended to receive antiviral therapy, a minority of cases received antivirals early in the course of illness.
- Top of page
- Conflicts of interest
The influenza A (H1N1)pdm09 virus (H1N1pdm09) began to circulate in the United States in April 2009,1 and in June 2009 the World Health Organization declared a global influenza pandemic. In the United States, a small focal pandemic wave in the spring was followed by a very large wave of widespread illness in all parts of the country in the fall.2 Although for most persons infected, influenza is a mild, self-limited illness, influenza epidemics and pandemics are associated with substantial morbidity and mortality in a population. This is particularly true in vulnerable populations, such as pregnant women, young children, the elderly, and those with certain underlying medical conditions.3 Identifying persons at greatest risk for severe outcomes from influenza helps to guide prevention and control efforts.4
The Centers for Disease Control and Prevention (CDC) monitored severe outcomes from H1N1pdm09 infection in the United States throughout the pandemic through individual reports and aggregate reporting by jurisdictions.5–7 A study of the characteristics of H1N1pdm09 influenza-associated deaths that occurred during April–July 2009 in the United States reported that 76% of deaths occurred in persons aged 18–64 years and 78% had underlying medical conditions.5 Chronic lung disease, including asthma, was the most common condition reported among cases aged ≥18 years (39%), while neurologic diseases were the most common conditions reported among cases aged <18 years (54%). This and other reports suggested that the age groups most at risk of severe H1N1pdm09 disease differed from those for seasonal influenza where the highest number of deaths is seen in persons aged ≥65 years.3,6–8 Based on experience from past pandemics, there was concern that in subsequent waves the H1N1pdm09 virus would become more virulent and cause more severe disease.9 Thus, surveillance for severe and fatal H1N1pdm09 cases was necessary at the start of the fall wave to detect potential changes in the epidemiologic patterns observed during the early months of the pandemic and ensure that vaccination and treatment recommendations remained targeted to those at greatest risk.5 To monitor characteristics associated with death from H1N1pdm09, a nationally representative study of deaths that occurred during September–October 2009 was conducted.
- Top of page
- Conflicts of interest
A total of ‘‘4053 influenza-associated deaths’’ were reported to CDC from September 1 to October 31, 2009, from all 50 states, the District of Columbia, and several large municipal areas.6 Because individual reports could not be collected for such a large number of cases, we selected a sample of deaths to identify changes in demographic and clinical characteristics of cases from spring to fall.5 Initial data from the spring suggested that 76% of fatal H1N1pdm09 cases had at least one underlying medical condition (this proportion later increased to 78% once analysis of all spring data was completed). Basing calculations on a 10% decrease in the prevalence of this characteristic and employing α = 0·05 and a desired power of 80%, we identified a sample size of 323 deaths. The probability of selection was proportional to the number of H1N1pdm09 laboratory-confirmed deaths either reported by or estimated to have occurred in each jurisdiction during this period. According to this sampling strategy, 40 states and New York City were asked to provide information for a specified number of H1N1pdm09-associated deaths; for the remaining jurisdictions, the number of laboratory-confirmed or estimated laboratory-confirmed deaths was <1 (i.e. zero or a fraction), and no case from that jurisdiction was included. Each jurisdiction was asked to randomly select the requested number from all laboratory-confirmed H1N1pdm09-associated deaths that occurred in the jurisdiction during the reporting period. The method of randomization was determined at the jurisdiction level.
We defined a case as death in a person of any age with laboratory confirmation of H1N1pdm09 virus infection occurring in the United States between September 1, 2009, and October 31, 2009. Laboratory confirmation included: a positive reverse transcriptase–polymerase chain reaction (RT-PCR) test for the H1N1pdm09 virus, an influenza A-positive RT-PCR test that was negative for human H1 and H3, a positive rapid antigen test for influenza A, a positive direct immunofluorescence assay, or a positive viral culture. State and local public health officials used a standard data collection form to collect and report information about demographics, date of illness onset, underlying medical conditions, complications of influenza preceding death, and up to seven causes of death. Sources of information used to complete reports included state case report forms, laboratory reports, patient medical records, death certificates, and autopsy reports. The principal investigator reviewed all forms; when data were missing or incorrect, they were corrected via personal communication with the submitting jurisdiction.
High-risk medical conditions were defined as those recognized by the Advisory Committee on Immunization Practices (ACIP) as conferring an increased risk of severe complications from seasonal influenza. These conditions include chronic pulmonary (including asthma), cardiovascular (excluding hypertension), renal, hepatic, neurologic/neuromuscular, hematologic, and metabolic disorders (including diabetes mellitus); immune suppression, including immune suppression caused by medications or human immunodeficiency virus; and pregnancy, including 6 weeks post-partum.4 Information was also collected about smoking, history of alcohol or substance abuse, obesity, and morbid obesity. Morbid obesity was ultimately added to the list of high-risk medical conditions that should be targeted for influenza vaccine in the 2010 ACIP recommendations.10 In cases aged 18 years and older, obesity was defined as body mass index (BMI) of ≥30 kg/m2 or use of the term “obesity” in the medical record; morbid obesity was defined as a BMI of ≥40 kg/m2 or use of the term “morbid obesity” in the medical record. For cases aged 2–17 years, obesity was defined as a BMI above the 95th percentile or use of the term “obesity” in the medical record.11 Obesity was not defined in cases aged <2 years, and morbid obesity was not defined in any patient <18 years old. Cases were defined as previously healthy if they did not have documentation of any ACIP high-risk condition, were not a current smoker, did not have a history of alcohol or substance abuse, and were not obese or morbidly obese. If information on any previous medical condition was available for a decedent, missing or unknown responses for other medical condition variables were considered to be negative responses; for all other variables, missing or unknown responses were excluded from the denominator. Medical conditions and causes of death were reviewed and categorized by physician-epidemiologists. Occupation was categorized according to the occupational risk pyramid for pandemic influenza, which classifies occupations according to the likelihood of employees’ exposure to pandemic influenza.12
Analysis was conducted using sas 9.2 statistical software (Research Triangle Institute, Cary, NC, USA). Statistical differences in categorical variables were evaluated using a chi-square test and in continuous variables a Wilcoxon rank-sum test; statistical significance was set at alpha (α) = 0·05. As part of the emergency public health response to the pandemic, this case series was deemed to be non-research in accordance with the federal human subjects protection regulations as defined in Title 45 Code of Federal Regulations parts 46.101c and 46.102d and CDC’s Guidelines for Defining Public Health Research and Public Health Non-Research.
- Top of page
- Conflicts of interest
Among the 323 requested H1N1pdm09 associated deaths from 41 jurisdictions, reports that met the inclusion criteria were submitted for 302 (93%) deaths from 36 states and New York City (for a jurisdictional response rate of 90%). Cases were not submitted from the following states: Idaho, Kentucky, Maine, Maryland, Massachusetts, Missouri, Nebraska, New Hampshire, New Jersey, North Dakota, Rhode Island, Vermont, Wisconsin, and Wyoming. The median number of deaths provided by jurisdictions was six (range, 1–42). Four reports were excluded because the date of death did not occur in September or October 2009, and for 17 cases from four states, the requested data collection was not completed. Complete information was not reported for each case; therefore, denominators vary according to the number of cases for which data were available.
The median age was 45 years and ranged from 10 days to 86 years; 224 (74%) deaths occurred in persons aged 18–64 years (Figure 1). Among 294 (97%) cases with available race and ethnicity data, 156 (53%) were white, non-Hispanic (NH), 62 (21%) were black, NH, and 48 (16%) were Hispanic (Table 1). Among 203 (67%) cases for whom occupation information was available, 90 (44%) were considered non-working, 52 (26%) were students or children, and 61 (30%) were employed. Of the 61 cases who were employed and who were classified using the occupational risk pyramid for pandemic influenza, 5 (8·2%) were working in a high-risk occupation, 15 (25%) in a medium-risk occupation, and 41 (67%) were in the lower-risk occupational group.
|Age group (in years)|
|American Indian/Alaska native||16/294 (5)|
|Student or child||52/203 (26)|
|High risk***||5/61 (8)|
|Medium risk||15/61 (25)|
|Lower risk||41/61 (67)|
Underlying risk factors
Past medical history was reported for 297 (98%) cases, and 214 (72%) had an ACIP-defined high-risk underlying medical condition (Table 2). Of the 214 cases that had an ACIP underlying medical condition, 60 (28%) had one condition, 43 (20%) had two, and 111 (52%) had three or more. The median number of ACIP high-risk conditions reported among cases was 3 (range, 1–11). Among those 18 years of age and older (n = 254), the most common ACIP high-risk conditions were chronic lung disease (37%), metabolic disorders including diabetes (33%), and cardiovascular disease (24%). One adult woman who died was pregnant and seven women who died had delivered a baby during the preceding 6 weeks. Among those aged <18 years (n = 43), the most common medical conditions were chronic lung disease (37%) and neurological disorders (35%).
|Co-morbid conditions||All ages Frequency (%)||<18 years Frequency (%)||≥18 years Frequency (%)|
|Medical history reported||297/302 (98)||43/45 (96)||254/257 (99)|
|Chronic lung disease||110/297 (37)||16/43 (37)||94/254 (37)|
|Asthma||52/297 (18)||11/43 (26)||41/254 (16)|
|COPD||49/297 (17)||0/43 (0)||49/254 (19)|
|Other chronic lung||44/297 (15)||11/43 (26)||33/254 (13)|
|Cardiovascular disease||70/297 (24)||9/43 (21)||61/254 (24)|
|Neurologic disorder||62/297 (21)||15/43 (35)||47/254 (19)|
|Developmental delay||23/297 (7·7)||13/43 (30)||10/254 (3·9)|
|Neuromuscular disorder||29/297 (9·8)||8/43 (19)||21/254 (8·3)|
|Seizure disorder||27/297 (9·1)||11/43 (26)||16/254 (6·3)|
|Other neurologic||30/297 (10)||3/43 (7·0)||27/254 (11)|
|History of stroke||10/297 (3·4)||0/43 (0)||10/254 (3·9)|
|Pregnant||1/297 (0·34)||0/43 (0)||1/254 (0·39)|
|6 weeks post-partum||7/297 (2·4)||0/43 (0)||7/254 (2·8)|
|Metabolic disorders||87/297 (29)||3/43 (7)||84/254 (33)|
|Diabetes||75/297 (25)||0/43 (0)||75/254 (30)|
|Other metabolic||19/297 (6·4)||3/43 (7)||16/254 (6·3)|
|Immunosuppressive condition*||58/297 (20)||1/43 (2·3)||57/254 (22)|
|HIV/AIDS||6/297 (2·0)||0/43 (0)||6/254 (2·4)|
|Renal disease||41/297 (14)||2/43 (4·7)||39/254 (15)|
|Hematologic disorder||33/297 (11)||0/43 (0)||33/254 (13)|
|Hepatic disease||19/297 (6·4)||0/43 (0)||19/254 (7·5)|
|ACIP condition**||214/297 (72)||27/43 (63)||187/254 (74)|
|Obesity***||139/251 (55)||8/30 (27)||131/221 (59)|
|Morbid obesity†||56/221 (25)||–||56/221 (25)|
|ACIP condition or obesity||247/297 (83)||30/43 (70)||217/254 (85)|
|History of alcohol/substance abuse||33/184 (18)||0/37 (0)||33/147 (22)|
|Current smoker||38/213 (18)||0/38 (0)||38/175 (22)|
Among those aged ≥18 years, 131/221 (59%) were obese, 56/221 (25%) were morbidly obese, 33/147 (22%) had a history of alcohol or substance abuse, and 38/175 (22%) had been current smokers. There were 8/30 (27%) persons <18 years of age documented as obese. Among those without ACIP high-risk conditions for whom data were available, 28/53 (53%) were obese; among adults, 17/46 (37%) were morbidly obese, 6/28 (21%) had a history of alcohol or substance abuse, and 7/30 (23%) were current smokers. Among the 278 patients with information on both ACIP high-risk conditions and other factors, only 13 (4·7%) reported no conditions and were considered previously healthy; the majority 9/13 (69%) were <18 years of age, and none was 65 years of age or older.
With few exceptions, the prevalence of underlying medical conditions in adult cases from this series was not significantly different from adult cases from the spring (Table 3).
|Condition||Prevalence, general US adult population (%)||Prevalence among 2009 H1N1 adult deaths, spring (%)||Prevalence among 2009 H1N1 adult deaths, fall (%)||P-value, Spring versus Fall||References|
|Chronic obstructive pulmonary disorder||4·4||15||19||0·24||27|
|Chronic renal disease (stage III or IV)||1·7||14**||15**||0·79||27|
The median interval between symptom onset and hospitalization varied significantly by age and was 3 days (range, 0–22 days) among adults aged ≥18 years old and 1 day (range, 0–7 days) among children <18 years old (P = 0·01). Six cases had been hospitalized for three or more days before onset of their influenza symptoms and may have acquired influenza in the hospital. The median interval from symptom onset to death also varied significantly by age and was 12 days in adults (range, 0–109 days) and 6 days in children (range, 1–48 days) (P < 0·01). A total of 254/299 (85%) cases were hospitalized (Table 4). Of those hospitalized, 233/254 (91%) received intensive care unit (ICU) care and 224/254 (88%) required mechanical ventilation. Of those not hospitalized, 11/34 (32%) received outpatient medical care for their influenza-related illness. The most common location of death was the hospital (232/292; 80%), followed by hospice (26/292; 8·9%), the emergency department (20/292; 6·8%), and home (11/292; 3·8%).
|Outpatient provider visit noted||99/176 (56)|
|Admitted to ICU||233/254 (91)|
|Mechanical ventilation||224/254 (88)|
|Antiviral therapy||187/268 (70)|
|Within 2 days of onset of symptoms||48/153 (31)|
|H1N1pdm09 vaccination||2/178 (1)|
|Diagnosed with pneumonia||211/260 (81)|
|Radiographic evidence of pneumonia||142/163 (87)|
|Specified etiology||84/211 (39)|
|Viral pneumonia||42/84 (50)|
|Bacterial pneumonia||22/84 (26)|
|Both viral and bacterial pneumonia||20/84 (24)|
|Organism cultured from sterile site||39/263 (15)|
|Pulmonary hemorrhage or hemoptysis||26/217 (12)|
|Developed pulmonary embolism||13/213 (6·1)|
|New onset CHF||21/209 (10)|
|New onset MI||16/216 (7·4)|
|Diagnosis of ARDS||138/228 (61)|
|Location of death|
|Autopsy performed||70/217 (32)|
Treatment and prevention
Influenza antiviral agents were prescribed for 187/268 (70%) cases (Table 4). Receipt of influenza antiviral agents did not vary significantly by age; they were received by 23/39 (59%) cases aged <18 years, 140/198 (71%) cases aged 18–64, and 24/31 (77%) cases aged ≥65 years (P = 0·21). Receipt of antivirals did, however, vary significantly by race/ethnicity; they were received by 92/141 (65%) white, NHs, 42/59 (71%) black, NHs, and 35/41 (85%) Hispanics (P = 0·046). Among those who received influenza antiviral agents and for whom the interval from illness onset to start of antiviral treatment could be calculated, the median interval was 4 days, and 48/153 (31%) were treated within 2 days. The proportion of cases receiving antiviral agents within the recommended first 2 days after symptom onset was 11/20 (55%) for cases aged <18 years, 24/115 (21%) for cases aged 18–64 years old, and 13/18 (72%) for cases aged ≥65 years old (P < 0·01). Oseltamivir was used either alone or in combination with other influenza antiviral agents for 185/187 (99%) cases who received influenza antiviral therapy; one case received only peramivir and one received only zanamivir. The H1N1pdm09 vaccine was not widely available before November 2009, and only 2/178 (1·1%) cases were reported to have received H1N1pdm09 vaccine.
Sequelae, complications, and co-infections
A clinical diagnosis of pneumonia was reported for 211/260 (81%) cases, and among these 142/163 (87%) had radiographic evidence of pneumonia (Table 4). Pneumonia etiology was reported as viral in 42/84 (50%) cases, bacterial in 22/84 (26%) cases, and both viral and bacterial in 20/84 (24%) cases. Acute Respiratory Distress Syndrome (ARDS) was reported for the majority (61%) of cases. Hemoptysis or signs of pulmonary hemorrhage were reported in 26/217 (12%) cases, and pulmonary embolism was reported in 13/213 (6·1%) cases. Acute myocardial infarction during the course of H1N1pdm09 infection was reported in 16/216 (7·4%) cases, and 21/209 (10%) cases developed a new diagnosis of congestive heart failure during the course of illness.
Organisms were cultured from samples taken from normally sterile sites in 39/263 (15%) cases (Table 3). The most common organisms identified were methicillin-resistant Staphylococcus aureus (cultured from 10 cases), followed by Streptococcus species (spp.) (n = 7), Candida spp. (n = 5), Pseudomonas spp. (n = 4), methicillin-sensitive Staphylococcus aureus (3), Enterococcus spp. (3), and Klebsiella spp. (2).
Autopsy was performed for 70/217 (32%) cases (Table 4). Among cases with any cause of death listed, 231/256 (90%) had at least one pulmonary cause of death listed, including influenza 175/231 (76%), pneumonia 125/231 (54%), ARDS 66/231 (29%), and viral pneumonitis 12/231 (5%).
- Top of page
- Conflicts of interest
This H1N1pdm09 fatality case series is a nationally representative sample of deaths associated with H1N1pdm09 infection that occurred early in the fall pandemic wave during a period of widespread H1N1pdm09 activity in the United States. The majority of deaths occurred in the hospital among adults between the ages of 18–64 with underlying medical conditions; pneumonia and ARDS were common complications of infection. Most cases, and especially children, were admitted to the hospital within the first several days of symptom onset. Receipt of influenza antiviral therapy within 2 days of illness onset was more frequently reported in children and persons aged ≥65 years than in persons aged 18–64 years old.
The age distribution for H1N1pdm09-associated deaths was similar to the distribution observed during the spring 2009 pandemic wave.5,8 From April to July 2009, the median age of fatal cases was 43 years and 76% of all H1N1pdm09-associated deaths occurred in persons aged 18–64 years.5 In this case series, the median H1N1pdm09 decedent age was 45 years and 74% of all H1N1pdm09-associated deaths occurred in persons 18–64 years of age. Furthermore, studies from Germany,13 England,14 and Portugal,15 conducted at different times during the pandemic, demonstrated similar median ages among those who died from H1N1pdm09, ranging from 43 to 49 years. This age distribution differs markedly from that typically observed in outbreaks of seasonal influenza, where >90% of deaths occur in persons ≥65 years of age.3 This relative sparing of persons ≥65 years of age may be due to pre-existing immunity from previous exposure to H1N1 influenza strains closely related to the 1918 influenza virus.16,17 In addition, as has been reported,5,12,18 the majority of cases (72%) had one or more medical conditions that put them at risk of severe influenza; all persons over the age of 65 had at least one underlying medical condition.
Our study corroborates the findings of several other studies identifying obesity and morbid obesity as more common among persons with severe influenza than in the general US population.5,12,18,19 While 59% of adults in this sample were obese, the most recent National Health Interview Study demonstrated a prevalence of obesity of 28·3% in the US adult general population.20 Before the 2009 pandemic, obesity and morbid obesity were not considered risk factors for severe influenza; however, following the pandemic morbid obesity was added by the ACIP to the list of underlying conditions that confer increased risk for severe outcome. Although it appears that morbid obesity was more common among fall 2009 cases than spring 2009 cases, caution should be used when interpreting this finding. Morbid obesity was identified as a potential risk factor for severe illness early in the pandemic;19 thus increased reporting of this condition may have occurred in the fall study. Pregnancy and a history of cancer were less frequently reported in the fall when compared to the spring, and this may have been a result of prevention and treatment messages that were targeted to protect these populations when they were noted to be at risk in the spring.5
Information about smoking, alcohol, and substance abuse was collected in this study. Smoking was not more common among adults aged ≥18 years old in our case series than in the general US population (22% versus 19%).20 However, 33/184 (18%) of our cases had a history of alcohol or substance abuse, while the 2009 National Survey on Drug Use and Health found that 8·9% of the general US population aged 12 or older had alcohol or substance dependence or abuse in the past year. Although not directly comparable, this evidence suggests that alcohol and substance abuse may have been more common in H1N1pdm09 deaths than in the general public.21 Further investigation of smoking, alcohol, and substance abuse as potential risk factors for severe outcomes from influenza is warranted. As noted by Epstein et al.,22 people with clearly defined risk factors could be specially targeted for influenza vaccination, even within current universal vaccine recommendations.
While a majority of cases in our study received influenza antiviral treatment, one-third of those treated received influenza antiviral agents within the recommended 2 days of symptom onset. Most of those who were not treated within the recommended time frame were in the 18- to 64-year-old age group who accounted for 75% of the deaths in this series. Prompt empiric treatment with influenza antiviral agents within 2 days of influenza illness onset can reduce the risk of severe illness or death.23–25 The benefits of antiviral treatment are likely to be greatest if treatment is started as soon as possible after illness onset, and evidence for benefit is strongest in studies in which treatment was started within 2 days of illness onset. However, antiviral treatment for any person with confirmed or suspected influenza who requires hospitalization is recommended, even if the patient presents >2 days after illness onset.23–25 This study is subject to several limitations. First, only cases from 36 states and NYC were included in this analysis. Thus, it is possible but unlikely that the results from this analysis may not be generalizable to the entire United States, given the wide geographical distribution of participating states and the >90% sample participation rate. Second, case ascertainment might have been biased toward hospitalized patients because people who die outside the hospital are less likely to be tested for influenza.26 However, we encouraged participating states to use all sources of mortality data and to select randomly from all deaths that occurred during the study period; approximately 20% of deaths occurred in a location other than the hospital. Third, states had different methods for confirming and identifying influenza deaths and used different data sources. Therefore, case ascertainment methods and data quality may vary by state. Finally, for a given decedent, if information was reported for one or more medical conditions, other medical conditions for which information was missing or unknown were assumed to be negative. This may have underestimated the prevalence of the underlying medical conditions included in this study.
Because of concerns about increased virulence in a subsequent pandemic wave, we conducted this study at the start of the fall wave to determine whether the epidemiologic patterns observed during the early months of the pandemic would persist and to ensure that vaccination and treatment recommendations remained targeted to those at greatest risk. We found that the characteristics of persons dying with H1N1pdm09 infection were similar to those who had died with H1N1pdm09 early in the pandemic. Close monitoring of H1N1pdm09-associated deaths was vital to the understanding of patient characteristics that occurred commonly in persons who died with H1N1pdm09 infection and helped to ensure that vaccine and antiviral treatment would be targeted to populations most likely to benefit from their use.
- Top of page
- Conflicts of interest
We thank Naomi Drexler, Jennifer McQuiston, and Christine Lees for their efforts in the publication of this manuscript.
Conflicts of interest
- Top of page
- Conflicts of interest
The authors have no conflicts of interest.
- Top of page
- Conflicts of interest
- 4Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1–54.
- 5Epidemiology of 2009 Pandemic Influenza A (H1N1) deaths in the United States, April–July 2009. Clin Infect Dis 2011; 52(Suppl 1):860–868., , et al.
- 6Centers for Disease Control. Flu-related hospitalizations and deaths in the United States from April 2009–January 30, 2010. Available at http://www.cdc.gov/H1N1flu/hosp_deaths_ahdra.htm (Accessed 28 February 2011).
- 10Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1–62.
- 11National Center for Health Statistics. 2000 CDC growth charts: clinical growth charts. Available at http://www.cdc.gov/growthcharts (Accessed 28 February 2011).
- 12Occupational Safety and Health Administration. Guidance on preparing workplaces for an influenza pandemic. OSHA 3327-05R 2009. Available at http://www.osha.gov/Publications/influenza_pandemic.html (Accessed 28 February 2011).
- 13Mortality of 2009 pandemic influenza A(H1N1) in Germany. Euro Surveill 2010; 15:19741., , et al.
- 14Pandemic Influenza A(H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro Surveill 2010; 15:19571., , et al.
- 20Early release of selected estimates based on data from the 2010 National Health Interview Survey [online]. National Center for Health Statistics. 2011; Available at http://www.cdc.gov/nchs/nhis.htm (Accessed 16 July 2011)., , , .
- 21Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, MD: Office of Applied Studies (NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings), 2010.
- 25Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1–25.
- 26Centers for Disease Control and Prevention. Interim guidance for influenza surveillance: prioritizing RT-PCR testing in laboratories. Available at http://www.cdc.gov/h1n1flu/screening.htm (Accessed 7 April 2010).
- 27Summary health statistics for U.S. adults: National Health Interview Survey, 2008. Vital Health Stat 2009; 10:242., , .
- 29Estimated pregnancy rates by outcome for the United States, 1990–2004. Natl Vital Stat Rep 2008; 56:1–26., , et al.
- Top of page
- Conflicts of interest
Members of the 2009 Pandemic Influenza A (H1N1) Fatal Case Series Investigation Team: Jacquelyn P. Skinner (Alabama Department of Public Health, Montgomery, AL, USA), Louisa J Castrodale (Alaska Department of Health and Social Services, Anchorage, AK, USA), Steven Baty (Epidemic Intelligence Service, Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA, USA; Arizona Department of Health Services, Phoenix, AZ, USA), Haytham Safi (Arkansas Department of Health, Little Rock, AR, USA), Janice K. Louie (California Department of Public Health, Richmond, CA, USA), Karen E. Gieseker (Colorado Department of Public Health and Environment, Denver, CO, USA), Alan J. Siniscalchi (Connecticut Department of Public Health, Hartford, CT, USA), Mardea Caulcrick-Grimes (Delaware State Division of Public Health, Dover, DE, USA), Kate Goodin (Florida Department of Health, Tallahassee, FL, USA), Deborah M. Rapalo (Georgia Division of Public Health, Atlanta, GA, USA), Ranjani Rajan (Hawaii State Department of Health, Honolulu, HI, USA), Kenneth Soyemi (Illinois Department of Health, Springfield, IL, USA), Matthew D. Ritchey (Epidemic Intelligence Service, Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA, USA; Indiana State Department of Health, Indianapolis, IN, USA), Meghan L. Harris (Iowa Department of Public Health, Des Moines, IA, USA), Daniel Neises (Kansas Department of Health and Environment, Topeka, KS, USA), Julie Hand (Louisiana Office of Public Health, New Orleans, LA, USA), Susan Peters (Michigan Department of Community Health, Lansing, MI, USA), Kayla Nagle (Minnesota Department of Health, St. Paul, MN, USA), Jannifer G. Anderson (Mississippi State Department of Health, Jackson, MS, USA), Elton Mosher (Montana Department of Public Health, Helena, MT, USA), Carmen P. Ponce (Nevada State Health Division, Carson City, NV, USA), Deborah L. Thompson (New Mexico Department of Health, Santa Fe, NM, USA), Alaina Stoute (New York City Department of Health and Mental Hygiene, New York, NY, USA), Christine Barr (New York State Department of Health, Albany, NY, USA), Nicole Lee (North Carolina Department of Health, Raleigh, NC, USA), Brian E. Fowler (Ohio Department of Health, Columbus, OH, USA), Kristy K. Bradley (Oklahoma State Department of Health, Oklahoma City, OK, USA), Kirsten Waller (Pennsylvania Department of Health, Harrisburg, PA, USA), Brittanni Wright (South Carolina Department of Health and Environmental Control, Columbia, SC, USA), Christine L Hockett (South Dakota Department of Health, Pierre, SD, USA), Lesley Brannan (Texas Department of State Health Services, Austin, TX, USA), Valoree Vernon (Utah Department of Health, Salt Lake City, UT, USA), Marshall P. Vogt (Virginia Department of Health, Richmond, VA, USA), Kathryn H. Lofy (Washington State Department of Health, Olympia, WA, USA), and Danae Bixler (West Virginia Bureau for Public Health, Charleston, WV, USA).